Nour Al-Mozain: Highlights on Therapeutic Plateletpheresis in Thrombocytosis
Nour Al-Mozain, Hemopathologist, Consultant at King Faisal Specialist Hospital and Research Center, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Transfusion Medicine Reviews։
“Excited to share this collaborative important multicenter work on therapeutic plateletpheresis (TPP) in thrombocytosis, now published in Transfusion Medicine Reviews.
Highlights
- TPP remains a safe, rapid but transient intervention, best utilized as a bridge in symptomatic thrombocytosis while awaiting cytoreductive therapy
- Most patients treated had MPN-related thrombocytosis, often presenting with neurologic symptoms or thrombotic/bleeding complications.
- While platelet reduction goals were commonly achieved, clear outcome benefit beyond count reduction remains uncertain
Clinical takeaway:
TPP should be used in a guideline-informed manner, with emphasis on clinical symptoms rather than platelet count alone, and always integrated within a broader cytoreductive strategy.”
Title: Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience
Authors: Jensyn Cone Sullivan, Jay S. Raval, Nicole D. Zantek, David L. Allison, Gaurav Gupta, Caroline R. Alquist, Nour Al Mozain, Hlaing Tint, Louise Helander, Lisa Boggio, Jose Pérez-Carrillo, Kyle Annen
Find more posts featuring Nour Al-Mozain on Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring